6 Nephrology Headlines You Missed in August 2025

August 2025 delivered a wave of important updates in nephrology, spanning new US Food and Drug Administration (FDA) approvals, clinical trial readouts, and global public health insights. The FDA cleared 2 generic versions of iron sucrose injection for iron deficiency anemia in chronic kidney disease (CKD), expanding access to a widely used therapy, and also approved an updated REMS label for sparsentan (Filspari) in IgA nephropathy (IgAN), easing monitoring requirements for patients and clinicians.